Transgenic APP Mice
TgCRND8 mice were developed in the Westaway Lab at the CRND, University of Toronto and express a double mutant form of APP and exhibit robust, early-onset deposition of Aβ amyloid, as well as behavioural deficits (Chishti et al, J.Biol Chem 2001). These mice are patented (US patent 7,371,920). Research use is subject to completion of a Material Transfer Agreement (MTA). All enquiries should be directed to Sandra Aussem at the University of Toronto.